Registry follows adults with high cholesterol who take pitavastatin
Collects information on adults with high cholesterol prescribed pitavastatin, without changing their treatment.
Plain-language title generated from the registry record
Registry title: PMMHRI-Pitavastatin Registry
Key facts
- Where
- Lodz, PolandSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults who are taking pitavastatin for high cholesterol, following the 2021 Polish Lipid Guidelines. It only records data; no treatment is given.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Earlier treatment
- Must be taking pitavastatin, prescribed based on the 2021 Polish Lipid Guidelines.
Read by machine on 9 November 2026.
Where in Poland
- Polish Mother's Memorial Hospital - Research InstituteLodz, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Polish Mother Memorial Hospital Research Institute
- Trial code
- NCT06858982
- Record updated
- 5 March 2025
- Original description
The PMMHRI-Pitavastatin Registry is a non-interventional, single-center registry conducted at the Polish Mother's Memorial Hospital Research Institute (PMMHRI). Established in January 2024, the registry enrolls all patients from the Department of Cardiology and Adult Congenital Heart Diseases, the Department of Endocrinology, as well as outpatient cardiology and endocrinology clinics who are prescribed pitavastatin.Read full original descriptionShow less
The Polish Mother's Memorial Hospital Research Institute Pitavastatin Registry
The PMMHRI-Pitavastatin Registry is a non-interventional, single-center registry conducted at the Polish Mother's Memorial Hospital Research Institute (PMMHRI). Established in January 2024, the registry enrolls all patients from the Department of Cardiology and Adult Congenital Heart Diseases, the Department of Endocrinology, as well as outpatient cardiology and endocrinology clinics who are prescribed pitavastatin.
Inclusion: patient takling pitavastatin based on the 2021 Polish Lipid Guidelines.
Exclusion: -.